# Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab

Source: https://onco.cc/trials/nct06172036/  
OnCo record `nct06172036` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and leucovorin (folinic acid) in pancreatic cancer, run by Zhejiang University, not yet recruiting.

## Summary

Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab is a phase 2, randomised interventional study registered as NCT06172036 by Zhejiang University, with a registry enrolment figure of 180 participants, started 2024-01-20 and due to reach its primary completion in 2026-01-20. Interventions recorded: irinotecan liposome + oxaliplatin + 5-FU / LV; Adebellizumab. Conditions listed: Neoadjuvant Chemotherapy; Resectable Pancreatic Cancer. Primary outcome: 12-month EFS rate. Pancreatic eligibility wording from the registry: "V2 version), multidisciplinary and imaging evaluation for patients with resectable pancreatic cancer, resectable defined as: by imaging examination, the criteria of radical resection of tumor is no distant metastasis, the artery (trunk celiac, superior mesenteric artery or common hepatic artery), an". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: CAPT-02
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06172036
- Phase: 2
- Setting: A Multicenter, Multi-cohort, Randomized, Phase II Study of Irinotecan Liposome Combined With 5-FU / LV and Oxaliplatin for Resectable Pancreatic Cancer With or Without Addebelizumab
- Sponsor: Zhejiang University
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06172036: https://clinicaltrials.gov/study/NCT06172036

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06172036.json